Prescient Therapeutics CEO James McDonnell talked with Proactive about the company’s clinical and regulatory progress throughout 2025, and what investors can expect heading into 2026. The interview highlighted three core achievements: enrolling the first patient in the PTX-100 Phase 2 trial, receiving key regulatory designations, and strengthening the team. McDonnell described the first patient enrollment as “significant for patients” and a milestone that is “really driving the company forward.” The FDA’s fast track designation and European orphan drug status were key regulatory wins. “It strengthens our business case,” McDonnell said, as Prescient aims to accelerate the path to treatment access for a rare cancer. Financially, the company confirmed it is well-funded to reach its next set of milestones. McDonnell also addressed a common investor question, confirming that PTX-100 is “first in class and the only GGT-1 inhibitor in clinical development internationally.” Prescient will begin 2026 focused on implementation — expanding patient recruitment across global trial sites, including in Italy, where the company is working with Professor Luigi Zinzani.

Watch the full interview below.